InvestSMART

Noxopharm Limited (ASX: NOX) - Announcements

- Current share price for NOX : $0.055

ASX company news and announcements for Noxopharm Limited (NOX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Noxopharm Limited (NOX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Noxopharm Limited (NOX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Noxopharm Limited (NOX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$17 October 2017 Open Briefing Corporate Presentation 19 Oct 2017 8:33AM $0.420 $0.055 fallen by 86.90%
$17 Invitation to Open Briefing 13 Oct 2017 8:54AM $0.340 $0.055 fallen by 83.82%
$17 Establishment of Nyrada Inc. - Extraordinary General Meeting 4 Oct 2017 9:19AM $0.325 $0.055 fallen by 83.08%
$17 Australian NOX66 - Radiotherapy Study Opens 27 Sep 2017 8:23AM $0.320 $0.055 fallen by 82.81%
$17 Establishment of Nyrada Inc. 25 Sep 2017 8:41AM $0.340 $0.055 fallen by 83.82%
$17 Positive Clinical Outcomes for NOX66 at ESMO Conference 12 Sep 2017 8:19AM $0.335 $0.055 fallen by 83.58%
$17 Change in substantial holding 7 Sep 2017 5:07PM $0.320 $0.055 fallen by 82.81%
$17 Change in substantial holding 6 Sep 2017 11:19AM $0.330 $0.055 fallen by 83.33%
$17 Placement completed App 3B, s708 Notice, LR7.1A4(b) Notice 4 Sep 2017 9:25AM $0.325 $0.055 fallen by 83.08%
$17 NOX CEO Interview explains recent Brain Cancer Announcement 4 Sep 2017 8:39AM $0.325 $0.055 fallen by 83.08%
$17 Appendix 4E and Audited Financial Statements 31 Aug 2017 11:11AM $0.340 $0.055 fallen by 83.82%
$17 Corporate Governance Statement - Appendix 4G 31 Aug 2017 9:33AM $0.340 $0.055 fallen by 83.82%
$17 Corporate Governance Statement 31 Aug 2017 9:32AM $0.340 $0.055 fallen by 83.82%
$17 Important Brain Cancer Findings for NOX66 Program 29 Aug 2017 9:43AM $0.390 $0.055 fallen by 85.90%
$17 Reinstatement to Official Quotation 24 Aug 2017 9:48AM $0.430 $0.055 fallen by 87.21%
$17 Noxopharm raises $5.5 million to advance clinical program 24 Aug 2017 9:48AM $0.430 $0.055 fallen by 87.21%
$17 Suspension from Official Quotation 23 Aug 2017 9:30AM $0.430 $0.055 fallen by 87.21%
$17 Trading Halt Request 21 Aug 2017 9:01AM $0.430 $0.055 fallen by 87.21%
$17 Trading Halt 21 Aug 2017 9:01AM $0.430 $0.055 fallen by 87.21%
$17 NOX Corporate Presentation ahead of Conference 8 Aug 2017 8:21AM $0.350 $0.055 fallen by 84.29%
$17 Appendix 4C - quarterly 31 Jul 2017 10:37AM $0.380 $0.055 fallen by 85.53%
$17 NOX Research Report prepared by APP Securities 27 Jul 2017 11:13AM $0.380 $0.055 fallen by 85.53%
$17 CEO Interview with FNN - Singapore and HK Roadshow 25 Jul 2017 8:35AM $0.320 $0.055 fallen by 82.81%
$17 New Corporate Presentation 25 Jul 2017 8:27AM $0.320 $0.055 fallen by 82.81%
$17 Noxopharm provides update on NOX66 Clinical Trial Program 6 Jul 2017 8:53AM $0.360 $0.055 fallen by 84.72%

701 - 725 of 801 results

Page 29 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.